title: Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease.
abstract: BACKGROUND
  Radiofrequency energy has been used safely and successfully to eliminate accessory pathways in patients with the Wolff-Parkinson-White syndrome and the substrate for atrioventricular nodal reentrant tachycardia. However, this form of ablation has had only limited success in eliminating ventricular tachycardia in patients with structural heart disease. In contrast, direct-current catheter ablation has been used successfully to eliminate ventricular tachycardia in patients with and without structural heart disease. The purpose of this study was to test whether radiofrequency energy can safely and effectively ablate ventricular tachycardia in patients without structural heart disease.
  
  
  RESULTS
  Sixteen patients (nine women and seven men; mean age, 38 years; range, 18-55 years) without structural heart disease who had ventricular tachycardia underwent radiofrequency catheter ablation to eliminate the ventricular tachycardia. Two patients presented with syncope, nine with presyncope, and five with palpitations only. Mean duration of symptoms was 6.7 years (range, 0.5-20 years). Radiofrequency catheter ablation successfully eliminated ventricular tachycardia in 15 of 16 patients (94%). Sites of ventricular tachycardia origin included the high right ventricular outflow tract (12 patients), the right ventricular septum near the tricuspid valve (three patients), and the left ventricular septum (one patient). The only ablation failure was in a patient whose ventricular tachycardia arose from a region near the His bundle. An accurate pace map, early local endocardial activation, and firm catheter contact with endocardium were associated with successful ablation. Radiofrequency ablation did not cause arrhythmias, produced minimal cardiac enzyme rise, and resulted in no detectable change in cardiac function by Doppler echocardiography.
  
  
  CONCLUSIONS
  Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease is effective and safe and may be considered as early therapy in these patients.
authors.affiliation: Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis.
authors.forename: L S
authors.initials: LS
authors.lastname: Klein
authors.forename: H T
authors.initials: HT
authors.lastname: Shih
authors.forename: F K
authors.initials: FK
authors.lastname: Hackett
authors.forename: D P
authors.initials: DP
authors.lastname: Zipes
authors.forename: W M
authors.initials: WM
authors.lastname: Miles
mesh_terms: D000293:Adolescent; D000328:Adult; D002304:Cardiac Pacing, Artificial; D004594:Electrophysiology; D005260:Female; D006321:Heart / Q000503:physiopathology; D006801:Humans; D007545:Isoproterenol; D008297:Male; D008875:Middle Aged; D011846:Radio Waves; D013610:Tachycardia / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*
chemical_list: D007545:Isoproterenol